Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, Venetoclax, and Ponatinib in Ph+ AML or CML
NCT04188405Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, venetoclax, ponatinib in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started May 2020; status: completed.
02
Drugs
decitabinevenetoclaxponatinib
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT04188405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188405.